{"entity":{"id":"farletuzumab-ecteribulin","kind":"drug","name":"Farletuzumab ecteribulin","aka":["MORAb-202"],"tldr":"Farletuzumab ecteribulin is an antibody-drug conjugate from Eisai Inc., in registered phase 2 trials for metastatic cancer.","summary":"Farletuzumab ecteribulin is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Eisai Inc., in metastatic cancer. An antibody-drug conjugate: an antibody against a tumour surface protein carries a cytotoxic payload into the cell. The registry record does not state the target or payload; the trial entries below carry the sponsor's description. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-2","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of Farletuzumab ecteribulin","url":"https://clinicaltrials.gov/search?intr=Farletuzumab%20ecteribulin"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["eisai"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04300556"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"modality":"Antibody-drug conjugate","mechanism":"An antibody-drug conjugate: an antibody against a tumour surface protein carries a cytotoxic payload into the cell. The registry record does not state the target or payload; the trial entries below carry the sponsor's description.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/farletuzumab-ecteribulin/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"eisai","kind":"company","name":"Eisai","route":"/companies/eisai/"}],"trial":[{"id":"nct04300556","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types","route":"/trials/nct04300556/"}]}}